These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 2571459)

  • 1. Comparative sensitivities of purified preparations of lysyl oxidase and other amine oxidases to active site-directed enzyme inhibitors.
    Tang SS; Chichester CO; Kagan HM
    Connect Tissue Res; 1989; 19(1):93-103. PubMed ID: 2571459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of chronic administration of inhibitors of flavin and quinone amine oxidases on imidazoline I(1) receptor density in rat whole brain.
    Holt A; Todd KG; Baker GB
    Ann N Y Acad Sci; 2003 Dec; 1009():309-22. PubMed ID: 15028605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoacylcadaverines as substrates for both monoamine oxidase and diamine oxidase; low rates of activity.
    Suzuki O; Matsumoto T; Oya M; Katsumata Y; Stepita-Klauco M
    Experientia; 1980 May; 36(5):535-7. PubMed ID: 6769699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rational design of suicide substrates of amine oxidases.
    Palfreyman MG; McDonald IA; Bey P; Danzin C; Zreika M; Lyles GA; Fozard JR
    Biochem Soc Trans; 1986 Apr; 14(2):410-3. PubMed ID: 3086155
    [No Abstract]   [Full Text] [Related]  

  • 5. Enhancement of rat brain cytosolic monoamine oxidase activity by clorgyline. Comparison with (-)-deprenyl and MDL 72145.
    Azam M; Jain S; Baquer NZ
    Biochem Pharmacol; 1990 Nov; 40(10):2215-8. PubMed ID: 2123104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?
    Baker GB; Sowa B; Todd KG
    J Psychiatry Neurosci; 2007 Sep; 32(5):313-5. PubMed ID: 17823646
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction of human monocyte motility by lysyl oxidase.
    Lazarus HM; Cruikshank WW; Narasimhan N; Kagan HM; Center DM
    Matrix Biol; 1995 Dec; 14(9):727-31. PubMed ID: 8785587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human copper-dependent amine oxidases.
    Finney J; Moon HJ; Ronnebaum T; Lantz M; Mure M
    Arch Biochem Biophys; 2014 Mar; 546():19-32. PubMed ID: 24407025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential inhibition of six copper amine oxidases by a family of 4-(aryloxy)-2-butynamines: evidence for a new mode of inactivation.
    O'Connell KM; Langley DB; Shepard EM; Duff AP; Jeon HB; Sun G; Freeman HC; Guss JM; Sayre LM; Dooley DM
    Biochemistry; 2004 Aug; 43(34):10965-78. PubMed ID: 15323556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effect of 1,3,5-triphenyl-4,5-dihydro-(1H)-pyrazole derivatives on activity of amine oxidases.
    Manna F; Chimenti F; Bolasco A; Bizzarri B; Befani O; Pietrangeli P; Mondovi B; Turini P
    J Enzyme Inhib; 1998 Jun; 13(3):207-16. PubMed ID: 9629538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-specific expression of amine oxidases in breast cancer metastases.
    Cha YJ; Jung WH; Koo JS
    Tumour Biol; 2018 May; 40(5):1010428318776822. PubMed ID: 29775160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-pyrrolines are mechanism-based inactivators of the quinone-dependent amine oxidases but only substrates of the flavin-dependent amine oxidases.
    Lee Y; Ling KQ; Lu X; Silverman RB; Shepard EM; Dooley DM; Sayre LM
    J Am Chem Soc; 2002 Oct; 124(41):12135-43. PubMed ID: 12371853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guanabenz as inhibitor of copper-containing amine oxidases.
    Banchelli G; Bertocci B; Raimondi L; Soldani G; Del Tacca M; Buffoni F
    Agents Actions; 1986 Apr; 18(1-2):46-8. PubMed ID: 3088929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards the development of selective amine oxidase inhibitors. Mechanism-based inhibition of six copper containing amine oxidases.
    Shepard EM; Smith J; Elmore BO; Kuchar JA; Sayre LM; Dooley DM
    Eur J Biochem; 2002 Aug; 269(15):3645-58. PubMed ID: 12153561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple modes of catalysis-dependent inhibition and inactivation of aortic lysyl oxidase.
    Kagan HM; Soucy DM; Zoski CG; Resnick RJ; Tang SS
    Arch Biochem Biophys; 1983 Feb; 221(1):158-67. PubMed ID: 6131646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reaction of aortic lysyl oxidase with beta-aminopropionitrile.
    Tang SS; Trackman PC; Kagan HM
    J Biol Chem; 1983 Apr; 258(7):4331-8. PubMed ID: 6131892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification of enzymatically active human lysyl oxidase and lysyl oxidase-like protein from Escherichia coli inclusion bodies.
    Jung ST; Kim MS; Seo JY; Kim HC; Kim Y
    Protein Expr Purif; 2003 Oct; 31(2):240-6. PubMed ID: 14550642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
    Severina IS
    Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substrate specificity and inhibitor sensitivity of monoamine oxidase in rat kidney mitochondria.
    Lyles GA; Shaffer CJ
    Biochem Pharmacol; 1979 Apr; 28(7):1099-106. PubMed ID: 444267
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.